sciencedirect.com/science/articl…
Exciting news! Our lab's new paper is a testament to the passion and dedication of Ritu Trivedi, a former undergrad. Collaborating with Tim Miller & Matteo Gastaldi, she sparked some ideas that fueled our work on #MOGAD . 🙏 to Clarice & Angela, too!

This multicenter study explored the acute dynamics of brain MRI features of #MOGAD within a single attack and demonstrated 3 major findings. Read the article to learn more: bit.ly/3WtFMCN

This case revealed a presentation of MOGAD with melanoma without tumor MOG immunostaining. Authors highlight tocilizumab as a dual-purpose treatment of MOGAD and the neurologic immune-related adverse effect of immune checkpoint inhibitor treatment: bit.ly/3ybxWUh

If you haven't done so already, save the date for the inaugural ECTRIMS Pre-Day, leading up to #ECTRIMS2024 . Explore #PaediatricMS , #NMOSD , #MOGAD & beyond. Engage with experts & gain valuable insights. Explore the programme & secure your ticket TODAY 👉 bit.ly/3v7Kjzu

Sun et al. use a virtual histology approach to assess the pathophysiological basis of interregional differences in grey matter atrophy patterns in patients with multiple sclerosis, AQP4+ and AQP4- subtypes of NMOSD, and MOGAD. tinyurl.com/y324cv8m

New study from our lab: Is there an immunological cross-reactivity of antibodies to the myelin oligodendrocyte glycoprotein and coronaviruses? academic.oup.com/braincomms/art…

Hear from our very own Fabienne Brilot in this article ‘Australian researchers make strides in understanding little-known 'cousin of MS’ which we now know as #MOGAD !

sydney.edu.au/news-opinion/n…

A new breakthrough for unilateral optic neuritis patients in particular at onset…

Most popular read this week: CGRP-targeting therapies should now be considered as a first-line approach for #migraine prevention along with previous first-line treatments—without requiring prior failure of other classes of treatment: bit.ly/3UpveBJ

#NeuroTwitter

A comparison of optic neuritis in multiple sclerosis, anti-AQP4 neuromyelitis optica, and myelin oligodendrocyte glycoprotein associated disease (MOGAD) pubmed.ncbi.nlm.nih.gov/38708316/

Happy to share Laura Cacciaguerra et al study of #MOGAD lesion changes during attacks: ➡️ 10% of attacks have an initial normal MRI (radiologic lag) ➡️ MRI more dynamic than in #MS or #NMOSD with T2-Lesions often appearing & sometimes resolving within attacks👇neurology.org/doi/10.1212/WN…

Deep dive into the pathophysiologic differences between MOGAD, NMO and MS on a cellular level with Dr. Manohar Shroff.
#IPNTN #pedineurorad #neurorad

Check out this great case by Drs Syc-Mazurek & Zhao-Fleming Mayo Clinic Neurology Residency reporting #MOGAD with melanoma exacerbated by immune checkpoint inhibition ➡️ IL-6 blockade with tocilizumab worked perfectly for #MOGAD without reducing anti-tumor immune response👇neurology.org/doi/10.1212/NX…

So proud of our research fellow Nanthaya Tisavipat for successfully defending her Master's thesis on MOGAD! She has all the potential in the world and we are ecstatic she will be staying at Mayo Clinic Neuro for residency. Eoin Flanagan Deena Tajfirouz, MD Matt Starr, MD ANASTASIA ZEKERIDOU

Despite #MOGAD Awareness Month closing, we are still raising awareness! We spoke with Eoin Flanagan, of Mayo Clinic, specifically about spinal fluid testing for MOGAD diagnosis.

Learn more in our latest iteration of NeuroVoices! 🗣️🎙️ 🧠

📘 neurologylive.com/view/neurovoic…

Absolutely honoured to be a part of the best team in the world, The MOG Project! Thank you to UCB News for interviewing us, our partners, sponsors & doctors to talk all things #MOGAD & our organisation. Indeed a powerful video! ‘The Power of the Flock’ youtu.be/EaxR8K8qzJk?si…

Grab your tissues because you don’t want to miss this powerful video titled ‘The Power of the Flock’ constructed by UCB News about The MOG Project & #MOGAD . Dr John J. Chen, MD, PhD, Dr Jonathan Santoro, MD, Guthy-Jackson Fdn
Jenny Khazen, Becca Salky, SRNA, MGH Neurology, Julia & Andrea…

This #MOGnificentMonday , we have another feature story for #MOGADAwarenessMonth : Jim Broutman’s MOGAD Story: Opening the Door to a New Lease on Life!

Our own Chief Media Officer, Jim Broutman tells how his experience with MOGAD led down the road to his advocacy and participation…

April is MOGAD Awareness Month! #mogadawarenessmonth #MOGAD   #raredisease
 
MOGAD may be monophasic, where only one attack occurs, or it can be multiphasic, meaning additional attacks (or relapses) occur. It is a life-long disease but can be managed with preventative treatment.…